en · de · es · fr · pt
sr9009-notes.peptides3626.com › Guide › Mechanism And Preclinical Findings — Worked Examples

Mechanism And Preclinical Findings — Worked Examples

By Editorial Desk · published 2026-02-28 · last reviewed 2026-03-26 · Guide

circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-03-26. Where a claim depends on a specific study, the study is described rather than over-claimed.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Detection, Regulation, and Misconceptions

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Related pages on this site

Notes from published material

==== Two strategies for searching for intelligent signals ==== Kardashev then analyzed various models and hypotheses of the evolution of civilization. Answering the question of the Russian astronomer Iosif Shklovsky, who in an article published in 1977 entitled Possibility of the Intelligent Life in the Universe Being Unique found it strange that the "shock wave of intelligence" of a supercivilization had not yet reached the limits of the whole Universe, Kardashev put forward two explanatory hypotheses. In the first, he postulated that it would not be useful for a supercivilization to expand the space it occupies in order to maintain its activity, and in the second, it is possible that a civilization, instead of dispersing itself in space, would rather continue its activities of information analysis in order to discover new fundamental laws (such as the exploration of the microcosm, or black holes for example). However, such civilization activities require the use of abundant energy. According to the laws of thermodynamics, an important part of this consumed energy must be converted into radiation of a bolometric magnitude approximately equal to that of the radiation background surrounding the source. The spectral distribution of this intensity must be close to that of a black body. This would be a possible way to search for extraterrestrial civilizations. Such energy consumption would also require a large amount of solid matter for stellar engineering activities, which Kardashev called "cosmic miracles".

== Etymology and pronunciation == The word epithelium uses the Greek roots ἐπί (epi), "on" or "upon", and θηλή (thēlē), "nipple". Epithelium is so called because the name was originally used to describe the translucent covering of small "nipples" of tissue on the lip. The word has both mass and count senses; the plural form is epithelia.

=== Surgery === Surgical removal of the pituitary tumor is usually effective in lowering growth hormone levels. Two surgical procedures are available for use. The first is endonasal transsphenoidal surgery, which involves the surgeon reaching the pituitary through an incision in the nasal cavity wall. The wall is reached by passing through the nostrils with microsurgical instruments. The second method is transsphenoidal surgery during which an incision is made into the gum beneath the upper lip. Further incisions are made to cut through the septum to reach the nasal cavity, where the pituitary is located. Endonasal transsphenoidal surgery is a less invasive procedure with a shorter recovery time than the older method of transsphenoidal surgery, and the likelihood of removing the entire tumor is greater with reduced side effects. Consequently, endonasal transsphenoidal surgery is the more common surgical choice. These procedures normally relieve the pressure on the surrounding brain regions and lead to a lowering of GH levels. Surgery is most successful in people with blood GH levels below 40 ng/ml before the operation and with pituitary tumors no larger than 10 mm in diameter. Success depends on the skill and experience of the surgeon. The success rate also depends on what level of GH is defined as a cure. The best measure of surgical success is the normalization of GH and IGF-1 levels. Ideally, GH should be less than 2 ng/ml after an oral glucose load.

Sources: en.wikipedia.org

Background from the literature

=== Breaking the C-N bond and product release === The hydroxide ion joins with the carbon atom of the creatine's amidino group, creating a tetrahedral intermediate product. This intermediate product collapses and breaks the C-N bond, releasing urea. The remainder of the molecule rearranges to form sarcosine, and both products diffuse from the active site pocket.

Under the 1992 constitution, the president was elected by the Federal Assembly of Yugoslavia for a four-year term. After the constitutional amendments of 2000, direct elections for the office of President were introduced. Under the 2003 constitution, the president was once again elected by the Assembly of Serbia and Montenegro for a four-year term, this time at the proposal of the president and vice president of the assembly. The president of Serbia and Montenegro was a member of the Supreme Defence Council together with the president of Serbia and the president of Montenegro, and served automatically as chairman of the council of ministers. Previously, the president and the prime minister had to be from different republics; now, with the posts merged, the president of the assembly had to be from a different republic from the president of Serbia and Montenegro, who in turn could not come from the same republic for more than two consecutive terms of office. The results of the direct presidential elections of 2000 were as follows:

In 2010, the United States produced more sulfuric acid than any other inorganic industrial chemical. The principal use for the acid is the extraction of phosphate ores for the production of fertilizer manufacturing. Other applications of sulfuric acid include oil refining, wastewater processing, and mineral extraction.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network